"New Insights on Patient Responses to Breakthrough Schizophrenia Treatment"

A groundbreaking study from Tufts University reveals patient responses to the first new schizophrenia drug in decades, paving the way for more personalized treatments for psychosis.

• The study published in Nature (journal) examines patient responses to a new antipsychotic approved over a year ago, highlighting its impact on schizophrenia treatment.
• Led by Michael Halassa at Tufts University, the research focuses on understanding variations in responses among patients experiencing psychosis, including those with schizoaffective disorder and bipolar disorder.
• Utilizing data from electronic health records, this study identifies potential biological targets for personalized treatment strategies in managing schizophrenia and related conditions.